Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population.
Breast cancer
Ki-67
Single nucleotide polymorphism
Vascular endothelial growth factor
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
26
09
2020
accepted:
16
11
2020
pubmed:
5
1
2021
medline:
24
6
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
To investigate the associations of four commonly studied single nucleotide polymorphisms (SNP) of the vascular endothelial growth factor (VEGF), including -460T/C (rs833061), - 634G/C (rs2010963), - 2578C/A (rs699947), and +936T/C (rs3025039), with the incidence, aggressiveness, and tumor markers expression of breast cancer in the Northern China Han population. Followed the genomic DNA extraction, a total of 259 patients with breast cancer (case group) and 273 healthy women (control group) underwent genotyping by PCR-LDR SNP assays. The associations between VEGF gene polymorphisms and the incidence, aggressiveness, and tumor markers expression of breast cancer were analyzed. Significant differences were observed in allele frequency and genotype distribution of - 634G/C between breast cancer cases and healthy controls (p = 0.006, 0.013). Individuals who carry the G allele more likely had a lower risk of breast cancer (OR, 0.866, 95% CI 0.782-0.959). Compared with CC genotype carriers, women who had the CG and GG genotypes demonstrated a relatively lower risk (OR, 0.860, 95% CI 0.757-0.978, p = 0.022; OR, 0.778, 95% CI, 0.656-0.924, p = 0.004, respectively). When we stratified the group of patients according to the status of tumor markers, a significant association of - 634G/C SNP and Ki-67 expression was observed. The CC genotype carriers were more likely to be characterized by high expression of Ki-67 (p = 0.031). Further analysis showed that the - 460T/-634C/-2578C/+936C haplotype was more associated with a higher risk of breast cancer (OR, 1.445, 95% CI 1.123-1.859, p = 0.004), whereas the - 460T/- 634G/- 2578C/+936C one was associated with a lower risk (OR, 0.736, 95% CI 0.563-0.963, p = 0.025). In the present study, we concluded that VEGF gene - 634G/C polymorphism is related to the incidence of breast cancer in the Han population in Northern China and also might be associated with tumor proliferation index Ki-67.
Identifiants
pubmed: 33392836
doi: 10.1007/s10549-020-06024-3
pii: 10.1007/s10549-020-06024-3
doi:
Substances chimiques
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-156Subventions
Organisme : NSFC
ID : 81271647
Organisme : NSFC
ID : 81630048
Références
Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P (2014) Breast cancer statistics and markers. J Cancer Res Therapeut 10(3):506–511
Su J, Wang J, Luo J, Li H (2019) Ultrasound-mediated destruction of vascular endothelial growth factor (VEGF) targeted and paclitaxel loaded microbubbles for inhibition of human breast cancer cell MCF-7 proliferation. Mol Cell Probes 46:101415
doi: 10.1016/j.mcp.2019.06.005
Liu Y, Zhang J, Huang R, Feng WL, Kong YN, Xu F, Zhao L, Song QK, Li J, Zhang BN (2017) Influence of occupation and education level on breast cancer stage at diagnosis, and treatment options in China: a nationwide, multicenter 10-year epidemiological study. Medicine 96(15):e6641
doi: 10.1097/MD.0000000000006641
Al Balawi IA, Mir R, Abu-Duhier FM (2018) Potential impact of vascular endothelial growth factor gene variation (-2578C>A) on breast cancer susceptibility in saudi arabia: a case-control study. Asian Pac J Cancer Prev 19(4):1135–1143
pubmed: 29699375
pmcid: 6031782
Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, Zheng W (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15(6):1148–1152
doi: 10.1158/1055-9965.EPI-05-0871
Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16(9):3121–3128
doi: 10.1200/JCO.1998.16.9.3121
Roy H, Bhardwaj S, Ylä-Herttuala S (2006) Biology of vascular endothelial growth factors. Febs Letters 580(12):2879–2887
doi: 10.1016/j.febslet.2006.03.087
Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Edler L, Lubiński J, Scott RJ, Hamann U (2008) The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett 262(1):71–76
doi: 10.1016/j.canlet.2007.11.029
Su JB, Kim JW, Kang H, Hwang SG, Kim NK (2008) Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea. Anticancer Research 28(2B):1271–1276
Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8):1232–1235
doi: 10.1006/cyto.2000.0692
Wang K, Peng HL, Li LK (2012) Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Prostate Cancer: a Systematic Review with Meta-analysis. Asian Pacific J Cancer Prevent Apjcp 13(11):5665–5669
doi: 10.7314/APJCP.2012.13.11.5665
Zhou Y, Li N, Zhuang W, Wu X (2011) Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Gastric Cancer Risk in a Chinese Han Population. Molecular Carcinogenesis 50(3):184–188
doi: 10.1002/mc.20703
Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, Karakitsos P (2009) Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48(6):563–569
doi: 10.1002/mc.20495
García-Closas M, Malats N, Real FX, Yeager M, Chanock SJ (2007) Large-scale evaluation of candidate genes identifies associations between VEGF Polymorphisms and bladder cancer risk. Plos Genetics 3(2):e29
doi: 10.1371/journal.pgen.0030029
Su JL, Lee SY, Jeon HS, Sun HP, Park JY (2005) Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prevent 14(3):571–575
doi: 10.1158/1055-9965.EPI-04-0482
Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106(4):468–471
doi: 10.1002/ijc.11238
Jin Q (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res Off J Am Assoc Cancer Res 11(10):3647–3653
doi: 10.1158/1078-0432.CCR-04-1803
Rahoui J, Sbitti Y, Touil N, Laraqui A, Ibrahimi A, Rhrab B, Al Bouzidi A, Moussaoui Rahali D, Dehayni M, Ichou M et al (2014) The single nucleotide polymorphism +936 C/T VEGF is associated with human epidermal growth factor receptor 2 expression in Moroccan breast cancer women. Med Oncol 31(12):336
doi: 10.1007/s12032-014-0336-6
Wang K, Liu L, Zhu ZM, Shao JH, Xin L (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 56(2):167–173
doi: 10.1016/j.cyto.2011.06.018
Sa-Nguanraksa D, O-Charoenrat P (2012) The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci 13(12):14845–14864
doi: 10.3390/ijms131114845
Madisen L, Hoar DI, Holroyd CD, Crisp M, Hodes ME, Reynolds JF (1987) The effects of storage of blood and isolated DNA on the integrity of DNA. Am J Med Genet Part A 27(2):379–390
doi: 10.1002/ajmg.1320270216
Huang K, Tang W, Tang R, Xu Z, He Z, Li Z, Xu Y, Li X, He G, Feng G et al (2008) Positive association between OLIG2 and schizophrenia in the Chinese Han population. Hum Genet 122(6):659–660
doi: 10.1007/s00439-007-0434-z
Lelièvre L, Clézardin P, Magaud L, Roche L, Tubiana-Mathieu N, Tigaud JD, Topart D, Raban N, Mouret-Reynier MA, Mathevet P (2018) Comparative study of neoadjuvant chemotherapy with and without zometa for management of locally advanced breast cancer with serum VEGF as primary endpoint: the NEOZOL Study. Clin Breast Cancer 18(6):e1311–e1321
doi: 10.1016/j.clbc.2018.07.005
Kiso M, Tanaka S, Saji S, Toi M, Sato F (2018) Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Int J Cancer 143(11):2905–2918
doi: 10.1002/ijc.31645
Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR et al (2013) Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 108(5):1052–1060
doi: 10.1038/bjc.2013.69
Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10):795–803
doi: 10.1038/nrc909
Morabito A, Sarmiento R, Bonginelli P, Gasparini G (2004) Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol/hematol 49(2):91–107
doi: 10.1016/S1040-8428(03)00168-9
Salven P, Perhoniemi V, Tykkä H, Mäenpää H, Joensuu H (1999) Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 53(2):161–166
doi: 10.1023/A:1006178517505
Carpini JD, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13(3):279–279
doi: 10.1007/s10456-010-9171-3
Ma J, Hu W, Zhang P, Sun Y, Wang N, Teng X, Qiao Q (2015) The association between VEGF +936C/T and -634G/C polymorphisms and breast cancer susceptibility, tumor growth, and metastases: evidence from 20,728 subjects. Cancer Invest 33(7):312–317
doi: 10.3109/07357907.2015.1044664
O-Charoenrat P (2014) Vascular endothelial growth factor polymorphisms affect gene expression and tumor aggressiveness in patients with breast cancer. Mol Med Rep 9(3):1044–1048
doi: 10.3892/mmr.2014.1890
Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, Kummalue T, Rojananin S, Ratanawichhitrasin A, Prasarttong-Osoth P, Chuthatisith S, Pisarnturakit P, Aeumrithaicharoenchok W et al (2013) Vascular endothelial growth factor 634G/C polymorphism is associated with increased breast cancer risk and aggressiveness. Mol Med Rep 8(4):1242–1250
doi: 10.3892/mmr.2013.1607
Zhang H, Sui X, Zhou S, Hu L, Huang X (2019) About Correlation of conventional ultrasound characteristics of breast tumors with axillary lymph node metastasis and ki-67 expression in patients with breast cancer. J Ultrasound Med 38(9):2523
doi: 10.1002/jum.14930
Chung MJ, Lee JH, Kim SH, Suh YJ, Choi HJ (2016) Simple prediction model of axillary lymph node positivity after analyzing molecular and clinical factors in early breast cancer. Med (Baltimore) 95(20):e3689
doi: 10.1097/MD.0000000000003689
Oliveira C, Lourenço GJ, Silva PMR, Cardoso-Filho C, Favarelli MHC, GonçAles NSL, Gurgel MSC, Lima CSP (2011) Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumor Biol 32(2):295–300
doi: 10.1007/s13277-010-0121-x
Luo T, Chen L, He P, Hu QC, Zheng H (2013) Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a chinese population. Asian Pacific J Cancer Prevent Apjcp 14(4):2433–2437
doi: 10.7314/APJCP.2013.14.4.2433
Wang K, Liu L, Zhu ZM, Shao JH, Xin L (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 56(2):167–173
doi: 10.1016/j.cyto.2011.06.018
Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M (2008) Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111(1):157–163
doi: 10.1007/s10549-007-9755-9
Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8(2):R22
doi: 10.1186/bcr1400
Langsenlehner U, Wolf G, Langsenlehner T, Gerger A, Hofmann G, Clar H, Wascher TC, Paulweber B, Samonigg H, Krippl P (2008) Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat 109(2):297–304
doi: 10.1007/s10549-007-9655-z